Sign in to view Tangie’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Tangie’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Memphis, Tennessee, United States
Sign in to view Tangie’s full profile
Tangie can introduce you to 10+ people at St. Jude Children's Research Hospital
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
2K followers
500+ connections
Sign in to view Tangie’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Tangie
Tangie can introduce you to 10+ people at St. Jude Children's Research Hospital
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Tangie
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Tangie’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Activity
2K followers
-
Tangie Thomas shared thisTangie Thomas shared this"Managers — more than any other factor — influence team engagement and performance…70% of the variance in team engagement is determined solely by the manager.”To Retain Your Best Employees, Invest in Your Best ManagersTo Retain Your Best Employees, Invest in Your Best Managers
-
Tangie Thomas shared thisTangie Thomas shared thisVirtual St. Jude: Denise Roe, vice president of clinical research regulatory and quality, shares her experience participating in the hospital's first Talent Talks webinar. http://ow.ly/j7lj30kMVwU #hospitaljob
-
Tangie Thomas reacted on thisTangie Thomas reacted on thisCongratulations to Kyla Hampton on receiving the 2026 Dr. Brock Faulkner ’04 Memorial Scholarship in recognition of her graduate research in air quality related to cotton ginning! The Dr. Brock Faulkner ’04 Memorial Scholarship is a distinguished award within the Texas A&M University Department of Biological and Agricultural Engineering (BAEN), established to honor the legacy of Dr. Faulkner. This fellowship is awarded to an exceptional BAEN graduate student whose research advances the fields of air quality, post-harvest technology, and/or cotton production and processing. As a proud Cotton Crew alumnus, Dr. Faulkner left a lasting impact on the program, making it especially meaningful to see Kyla (current Cotton Crew member) recognized with this outstanding fellowship. Congratulations to Kyla on this well-deserved honor and for carrying forward a legacy of excellence in cotton engineering research.
-
Tangie Thomas liked thisTangie Thomas liked thisA lot of leadership lacks one thing: intention. People don’t know why their work matters. Teams feel disjointed. Conversations are happening, but there is no real communication. High-performing leadership starts here: 1) PURPOSE - Lead with Why Clarify your mission and values Align goals with deeper meaning Inspire with vision and storytelling Lean in when: ↳ Team lacks motivation ↳ During change or strategic shifts ↳ Setting long-term direction 2) PRESENCE - Lead Yourself First Practice emotional regulation Communicate authentically Stay grounded in uncertainty Lean in when: ↳ Tensions run high ↳ Communication breaks down ↳ During crisis or key decisions 3) PEOPLE - Empower Others Build psychological safety Coach through feedback Recognize and develop talent Lean in when: ↳ Morale is low ↳ Facing retention or onboarding ↳ Growing a team or culture 4) PERFORMANCE - Execute with Clarity Set clear priorities and metrics Align strategy with execution Optimize through feedback Lean in when: ↳ Progress stalls ↳ Reviewing KPIs/OKRs ↳ Scaling or pivoting strategy When you lead with intention, results follow. Which P do you need to lean into right now? I share weekly insights with 900+ high performers every Tuesday: https://lnkd.in/ekr6ht3h
-
Tangie Thomas liked thisTangie Thomas liked thisEvery detail matters when you’re building a place for patient care. This week, we sat down with our builder team to begin shaping the space that will become Victory Family Medicine. From layout to flow, each decision is being made with one goal in mind—creating an environment where patients feel comfortable, cared for, and truly known. There’s still a lot ahead, but it’s exciting to see the vision beginning to take form. ✨ Opening Summer 2026 📍 Rockwall & surrounding communities
-
Tangie Thomas reacted on thisTangie Thomas reacted on thisCatina Bradley Latham, SVP, chief community health transformation officer, and Tyler Bauer, SVP, system ambulatory operations, have been named by Crain's Chicago Business as Notable Leaders in Health Care 2026. Catina is expanding community health access across the South Side and south suburbs; Tyler is driving AI-powered innovation that is transforming how patients connect with care. Congratulations for this well-deserved recognition! https://lnkd.in/g_t4vgdr
-
Tangie Thomas reacted on thisTangie Thomas reacted on thisOne thing I’ve learned working with and in smaller biotech teams: Strong clinical data leadership is rarely just about having the “right” system or the “right” vendor. It’s about having the right structure around the work. In lean organizations, clinical data often sits in a complicated reality: ▪️Limited internal bandwidth ▪️Multiple external vendors ▪️Growing study complexity ▪️Evolving timelines ▪️Cross-functional dependencies everywhere And no room for the avoidable operational friction. Sound familiar? That’s why strong clinical data leadership today has to be more than database oversight or deliverable tracking. It usually means someone is actively creating clarity around: 🔹Who owns what 🔹How external data is integrated and reviewed 🔹How issues are escalated 🔹How vendors are being overseen 🔹How standards are applied consistently 🔹How cross-functional teams stay aligned as the study evolves In my experience, this is where many teams feel the gap. Not because people aren’t working hard. Not because the vendors are necessarily underperforming. But because the organization needs someone who can connect: ✔️ Strategy ✔️ Execution ✔️ Governance ✔️ Infrastructure ✔️ Day-to-day decision-making That’s often the difference between: ❌ Constantly reacting and ✅ Running a clinical data function that can successfully scale And in a lean biotech, that leadership needs to be BOTH strategic enough to build the model AND hands-on enough to make it work in real time. That’s one of the biggest shifts I’m seeing right now: Organizations don’t just need clinical data support. They need practical clinical data management leadership that can operate in the middle of complexity. Leadership who can build the plane while they fly it. Let's talk about it! In smaller biotech environments, where do you see the biggest clinical data leadership gap the most often? Vendor oversight, ownership clarity, external data integration, process design, cross-functional alignment? Something else? #ClinicalDataManagement #ClinicalData #Biotech #ClinicalTrials #DataGovernance #VendorOversight #ExternalData #ClinicalOperations
-
Tangie Thomas liked thisTangie Thomas liked thisOne of the biggest shifts in clinical development is that clinical data is no longer owned by one function. And many organizations are still operating as if it is. There was a time when Clinical Data Management could be viewed more narrowly; centered primarily around EDC, CRF data flow, query management, and database deliverables. That’s no longer the full picture. Today, clinical data is shaped by a much broader ecosystem: • CROs and data management vendors • Central labs • Imaging vendors • ePRO/eCOA platforms • Biomarkers and specialty data providers • Biostats, medical monitoring, Clinical Operations, QA, regulatory, and technology partners Which means the challenge isn’t just managing data. It’s managing ownership, accountability, and decision-making across the people and processes surrounding the data. That’s where I see many teams struggle. Not because people aren’t capable. Not because systems are always wrong. But because the operating model hasn’t fully caught up with the complexity of how clinical data is actually created, reviewed, integrated, and used today. That often shows up as: ‣ Unclear ownership across functions ‣ Inconsistent expectations between internal teams and vendors ‣ Fragmented issue escalation ‣ Gaps in external data oversight ‣ Delayed decision-making because no one is fully aligned As studies become more complex, I think one of the most important capabilities for sponsors is this: Building a clinical data model that reflects how the work really happens now; not how it used to happen. That means: ✔️Clearer cross-functional ownership ✔️Stronger governance ✔️Better-defined handoffs ✔️Intentional oversight across internal and external stakeholders Because today, clinical data isn’t just a deliverable. It’s an ecosystem. Let's talk about it! Where do you think ownership breaks down most often today? Between functions internally, between sponsors and vendors, or around external data sources? Something else? #ClinicalDataManagement #ClinicalData #Biotech #ClinicalTrials #DataGovernance #ExternalData #ClinicalOperations
-
Tangie Thomas liked thisTangie Thomas liked thisAs I continue building Clinical Data Excellence Consulting, I wanted to share a little more clearly what I do and how I help. CDX Consulting supports biotech and academic research organizations that need both strategic guidance and hands-on clinical data leadership. As clinical trials become more complex, many teams are facing the same challenges: • Fragmented external data • Unclear ownership across vendors and functions • Inconsistent standards and processes • Manual reconciliation and reactive workflows • Operating models that don’t scale with study complexity That’s where CDX Consulting comes in. I work with organizations that need support across both strategy and execution, including: • Strategic clinical data leadership • Hands-on / fractional CDM support • External data governance and vendor oversight • Clinical data operating model design • Process and standards development • Cross-functional alignment across clinical data stakeholders My goal is simple: help organizations build greater clarity, consistency, and scalability across clinical data operations. In many cases, that means more than recommendations. It means rolling up my sleeves and helping teams solve real operational challenges in practical ways. If your team is navigating increasing clinical data complexity and could benefit from strategic support, embedded leadership, or a stronger operating model, I’d be happy to connect. #ClinicalDataManagement #ClinicalTrials #Biotech #AcademicResearch #ExternalData #DataGovernance #ClinicalOperations #CDXConsulting
-
Tangie Thomas liked thisTangie Thomas liked thisI’m excited to share that I’m running for School Board in the Collierville School District. As a parent and active member of our community, I care deeply about keeping our schools strong—focusing on academic excellence, supporting great teachers, engaging families, and being responsible with taxpayer dollars. If you believe in that vision too, I’d be grateful for your support. https://lnkd.in/g39-iRNF
-
Tangie Thomas liked thisCongrats to my favorite Howard alum! Keep rising!Howard University Cathy Hughes School of Communications
Howard University Cathy Hughes School of Communications
3moTangie Thomas liked thisHonored to celebrate Black History Month by spotlighting one of our outstanding alumni, Nell Reed! Her leadership in marketing and communications and her commitment to community impact continue to uplift and inspire the Bison community.
Experience & Education
-
St. Jude Children's Research Hospital
**** ********** ******** ****** **********
-
***** ****** ******** ********* * *********** *********** ********* ******* ****
********
-
***** ****** ******** *********
****** *******
-
*** ****** ********** ********** ****** ** ******** *** ****** ********
*** ************ undefined
-
-
********** **********
** ********** ***********
-
View Tangie’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Tangie’s full profile
-
See who you know in common
-
Get introduced
-
Contact Tangie directly
Other similar profiles
Explore more posts
-
Frank Michael Odia MBA MSHR
Oncology Executive Search • 31K followers
📈 The FDA’s August 2025 draft guidance on oncology trials signaled something bigger than a “regulatory update.” The guidance pushes for: • Overall Survival (OS) assessment in all randomized oncology trials — even when OS isn’t the primary endpoint (FDA: “Approaches to Assessment of Overall Survival in Oncology Clinical Trials,” Aug 2025) • More rigorous evidence to support accelerated endpoints (Summarized by Charles River Labs, 2025) • Stronger confirmatory pathways and earlier statistical alignment (Targeted Oncology analysis, 2025) Most people see this as paperwork. Executives should see it as an operational challenge: • earlier statistical alignment • cleaner trial design • tighter evidence integration • faster cross-functional decision-making This is a leadership issue, not a documentation issue. The organizations that adapt now will avoid the delays that everyone else will face in 2026–2027. Oncology Executive Search fodia@oncologyexecutivesearch.com #OncologyLeadership #ClinicalDevelopment #RegulatoryStrategy #BiotechLeadership
14
-
TRIMEDX
26K followers
Career growth often starts with curiosity—and the courage to take a step outside your comfort zone. Lakadria, a #TRIMEDX associate, transitioned from #MME to #ClinicalEngineering. While she was initially nervous about the change, she found mentors who supported her and training opportunities to build her confidence. Now, she encourages others to take the leap toward growth and development, even if it’s scary. #TRIMEDXculture https://hubs.ly/Q040gkDV0
24
2 Comments -
Olivier Simon
Nucleus Network • 4K followers
Accelerated regulatory pathways only create value if regulatory risk is controlled upstream. Following last week’s MHRA announcement on faster Phase I assessments in the UK, one reality deserves more attention from sponsors planning early development in 2026: "Regulatory speed at agency level only translates into real acceleration if the protocol and CTA package are right first time". Yet procurement discussions in early phase often still focus on: - Cost per subject - Day rates - CRO headcount What is less visible, but far more impactful, are the true cost drivers: - Regulatory delays due to avoidable questions or amendments - Additional internal and external resources to respond to regulators - Missed development, financing, or partnering milestones To put this into perspective, a "15-day CTA delay can easily cost more than the entire price difference between two CRO bids", once internal team time, CRO re-work, manufacturing knock-on effects, and investor or board timelines are taken into account. This is especially critical for: - VC-backed biotechs operating under tight cash and milestone pressure - Public companies with fixed reporting expectations - First-in-human, SAD/MAD, or adaptive Phase I studies where regulatory scrutiny is highest At Hammersmith Medicines Research Ltd Nucleus Network UK (HMR), we focus on reducing regulatory friction at its source—through regulator-aligned protocol design, integrated early-phase strategy, and close interaction with MHRA expectations. As the UK moves to even faster Phase I timelines, the real differentiator will not be the lowest CRO rate, but the ability to control regulatory risk and protect development timelines. If you are planning early-phase or first-in-human studies and want to discuss how regulatory strategy impacts timelines and cost in practice, feel free to contact me. #ClinicalTrials #PhaseI #RegulatoryStrategy #EarlyDevelopment #MHRA #Biotech #Pharma #NucleusNetwork #HMR
10
1 Comment -
Syneos Health
802K followers
Modern CRAs are shifting from travel and SDV-heavy tasks to becoming strategic site partners aligned with ICH E6(R3). This new paper explores how sponsors and CROs can modernize monitoring models, reduce site burden and strengthen CRA-site relationships — powered by technology, central monitoring and risk-proportionate approaches. Read the full piece for a blueprint to advance CRA capabilities, improve efficiency and build a future-ready monitoring model: https://lnkd.in/eKpR88vz #SyneosHealth #ClinicalResearchAssociate #ClinicalTrials #ClinicalResearchOrganization #PatientSafety #PatientsandSites
76
-
Bioforum the Data Masters
24K followers
👏 Bioforum leadership milestone: our President, Michael Goedde, has launched a new book, Mastering Clinical Data Management. Michael wrote this book from his perspective as an industry leader with decades of experience in CDM. Throughout his career, he has focused on building high-performing teams, solving complex delivery challenges, and raising the global standards for data quality and execution. This extensive expertise is the same foundation he uses to lead Bioforum today. 🔗 Learn more: https://bit.ly/4cJqWAi We’re also marking the launch at upcoming conferences and scheduling meetings with CDM, Clinical Operations, and biometrics leaders. #ACDM: 15- 18 March | Berlin, Germany #PHUSE: 22-26 March | Austin, Texas 👉 Schedule a meeting: https://bit.ly/46cF8Ol #ClinicalDataManagement #CDM #ClinicalTrials #Biometrics #DataQuality
82
7 Comments -
Recepta Clinical Research
126 followers
To avoid study start-up delays, consider running parallel ethics submissions, budget evaluations, and operational setups. Proactive planning ensures timely patient recruitment and clear workflows empower your team to excel! #ClinicalResesarch #ClinicalTrials #StudyStartup #ClinicalResearchOperations
-
Santiago Calandri
Fortrea • 10K followers
🎤 New Podcast Alert from Fortrea! 🎤 Tune in to the second episode of our "Sustainability in Clinical Trials" series! 🎧 This 2-part episode delves into how sustainability strategies drive speed and efficiency in drug development. Host John Kennett is joined by Carly Santer, Andrea Robinson-Smith, Ida Corneliusson, Keith Moore, Clare Campbell-Cooper, and Marlene Knupfer to discuss the obstacles slowing progress and share their thoughts on what listeners can do today to make a difference. They also share delightful anecdotes about where things have gone wonderfully right. 🌳 🎧Listen: https://gag.gl/zM0BlN #Sustainability #ClinicalTrials #Podcast #Fortrea
-
Prior Authorization | PACS - ACMA
9K followers
👉55% improvement in prior authorization approvals after denial appeals, that’s what PACS-certified professionals reported after completing the PACS® program. This jump in success rates is exactly why the Top 100 Pharma Companies trust the PACS® program to empower their field reimbursement and market access teams to deliver faster patient access and better outcomes. Explore more here https://hubs.ly/Q03Clgxk0 #PriorAuthorization #PACS #HealthcareAccess #ValueBasedCare #HealthPolicy #PayerStrategy #UtilizationManagement #ACMA
5
-
Bryan Blair
GQR • 23K followers
Layoffs are up—but signal is still hiring Yes, cuts are real: Tessera Therapeutics (-17%, ~59 people), Generate:Biomedicines (-10%, ~33), Sarepta Therapeutics (~500 in a broader restructure). But capital is still flowing to assets and operators that reduce risk faster: • Dispatch Bio launched with $216M to chase a “universal” solid‑tumor CAR T via its Flare platform (label tumors + weaken micro‑environment). • Platform megadeals continue (e.g., Novartis/Matchpoint Therapeutics), while acquirers kill weak programs quickly (Roche/CT‑173). Translation: lean teams with crisp milestones win the budget war. Candidate playbook (career delta > job title) Lead with outcomes, not nouns. “Cut Phase 2 screen‑fail rate from 37%→22% in 2 quarters; saved 2.5 months” beats “Program Manager.” Show the predictability premium. Include regulatory receipts: FDA meeting minutes you drove, a labeling win, an inspection issue closed. Prove capital literacy. One slide that ties your milestone to cash burn saved or valuation step (e.g., “first‑in‑human PK bridge de‑risks P2 dose → unlocks $20M tranche”). Be acquisition‑ready. If your work maps to a buyer’s gap (e.g., RSV/hMPV, obesity, IBD), say it plainly. References that sell. Pick a cross‑functional leader (ClinOps/CMC/Reg) who can attest to how you de‑risked the next readout. Hiring manager filters (use in screening calls) – “Walk me through the last ‘no‑go’ you recommended and the dollars/time it saved.” – “What pre‑specification did you insist on that prevented a post‑hoc p‑value fire drill?” – “Show me a supplier pivot you executed (Asia → US/EU) and the cost delta.” This market isn’t anti‑talent—it’s anti‑waste. The teams that win are shipping clarity, speed, and receipts. 💡 If you were riffing a 90‑day plan for a lean TranCend‑style team, what two risks would you retire first? #BiotechJobs #LifeSciences #ClinicalTrials #CMC #Careers
4
-
Advarra
78K followers
Every IRB submission tells a story. With nearly a decade in clinical research, Francine Lopez, B.S., CCRP sees beyond the paperwork to the people and purpose behind it: https://hubs.la/Q043qlFQ0 As senior manager of client services at Advarra, Francine leads with empathy, urgency, and collaboration to help studies move from idea to impact. Her approach is grounded in three principles: 🔹 See the person. Every document represents a patient, a family, a future. 🔹 Lead with urgency. Timely, high-quality reviews can mean faster access to care. 🔹 Work as one team. Cross-functional collaboration keeps research moving forward. Hear more from Francine in our latest IRB Voices feature: https://hubs.la/Q043qlFQ0 #clinicaltrials #clinicalresearch #IRB #clientservices #Advarra #patientfocus
62
1 Comment -
Helaine Resnick, PhD, MPH
Resnick, Chodorow &… • 875 followers
Resnick, Chodorow, and Associates is pleased to share a white paper on chronic kidney disease (CKD) that we produced for our longstanding client, NCQA. This report highlights critical gaps in CKD screening, diagnosis, and management, and examines CKD in the broader context of the cardiovascular-kidney-metabolic (CKM) syndrome. It offers approaches to addressing CKD care gaps and a forward-thinking framework that may ultimately be used for CKD quality measures. Interested in reading the full report? Check it out here: https://lnkd.in/eAiDp5aG
8
4 Comments -
International Psoriasis Council
6K followers
🎙️ Join #IPCPresident Bruce Strober and #IPCCouncilor Linda Stein Gold on this ReachMD podcast as they break down the new #IPC consensus on reclassifying psoriasis severity and redefining failure of topical therapies. From high-impact disease sites and BSA >10% to inadequate response to topicals, this discussion clarifies which patients may benefit from earlier systemic therapy, including IL-23 and IL-17 inhibitors, and how to apply the framework confidently in practice. Listen to the full podcast: https://lnkd.in/gHxm9tPi #Psoriasis #Dermatology #SystemicTherapy #IL23 #IL17 #ClinicalGuidance #MedicalEducation
10
-
GIPAM
991 followers
Scientific Rigor🧪, Delivered in Time⏱️ : How Impact in HEOR & RWE Is Created 🚀 In every HEOR and RWE project, we are guided by scientific rigor and clinical relevance. When paired with timely, pragmatic delivery, high-quality evidence can support access and reimbursement decisions and help inform real-world patient care. In HEOR & RWE, data is never perfect. As our consultant Chen-Chia Pan highlights, impact comes not from chasing the perfect answer, but from delivering rigorous, decision-relevant evidence within the time frames decisions require. This balance between scientific excellence and timely delivery, shapes how we work at GIPAM and how our experts contribute across HEOR & RWE projects!⚖️ 🎥 In this interview, our experts share how we translate scientific excellence into actionable insights under real-world constraints. How do you balance rigor and timeliness in HEOR & RWE?🧪⏱️ #HEOR #RWE #ScientificExcellence #EvidenceGeneration #HealthcareDecisionMaking #MarketAccess #HealthcareImpact
10
-
Mitchell Efros
Verified Clinical Trials • 12K followers
💡 Duplicate enrollment in clinical trials isn’t just a nuisance—it’s a real risk to data integrity. Verified Clinical Trials (VCT) is excited to be attending ObesityWeek in Atlanta! GLP-1, obesity, and diabetes clinical trials are especially prone to duplicate subjects: Many competing studies are recruiting from the same patient pool. Motivated participants may seek the active drug rather than placebo. Some subjects enroll at multiple sites—or even across different sponsors. This undermines trial outcomes, distorts placebo responses, and puts sponsors and CROs at risk. 🔎 VCT is the only cross-sponsor, cross-therapeutic solution that detects duplicate enrollment and protocol violations at the time of screening. We protect study integrity so your data stays clean and reliable. If you’ll be in Atlanta, let’s connect and talk about how VCT can safeguard your GLP-1, obesity, and diabetes studies. #ObesityWeek #GLP1 #ClinicalTrials #DataIntegrity #DiabetesResearch #ObesityResearch #ClinicalResearch
2
-
Mitchell Efros
Verified Clinical Trials • 12K followers
💡 Duplicate enrollment in clinical trials isn’t just a nuisance—it’s a real risk to data integrity. Verified Clinical Trials (VCT) is excited to be attending ObesityWeek in Atlanta! GLP-1, obesity, and diabetes clinical trials are especially prone to duplicate subjects: Many competing studies are recruiting from the same patient pool. Motivated participants may seek the active drug rather than placebo. Some subjects enroll at multiple sites—or even across different sponsors. This undermines trial outcomes, distorts placebo responses, and puts sponsors and CROs at risk. 🔎 VCT is the only cross-sponsor, cross-therapeutic solution that detects duplicate enrollment and protocol violations at the time of screening. We protect study integrity so your data stays clean and reliable. If you’ll be in Atlanta, let’s connect and talk about how VCT can safeguard your GLP-1, obesity, and diabetes studies. #ObesityWeek #GLP1 #ClinicalTrials #DataIntegrity #DiabetesResearch #ObesityResearch #ClinicalResearch
13
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Tangie Thomas
-
Tangie Thomas
Humble, TX -
Tangie Thomas
United States -
Tangie Thomas, DMSc, PA-C
Atlanta Metropolitan Area -
Tangie Thomas
Nashville, TN
9 others named Tangie Thomas are on LinkedIn
See others named Tangie Thomas